Riskpilot← Back to searchSign inGet full accessUkales Hälsokonsult AB
ABDissolvedOrg 5569796955SundsvallMedical specialists activities · NACE 8622Est. 20140 employees
Revenue 2024
SEK 0
EBITDA margin
—
+4% vs 2023
Equity ratio
87.3%
Financial strength
Net profit 2024
SEK 892K
+85% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -26K | +4% |
| Net profit | SEK 892K | +85% |
| Total assets | SEK 3M | +39% |
| Equity | SEK 2,6M | +36% |
| Employees | 0 | — |
Legal name
Ukales Hälsokonsult AB
Org number
5569796955
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
18 augusti 2014
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Medicinsk konsultverksamhet inkluderad utbildning för olika yrkeskategorier och patientvård. Bolaget ska även bedriva handel och förvaltning med värdepapper samt därmed förenlig verksamhet.
Address
Sundsvall
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −24 | −29 | −28 | −27 | −26 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −24 | −29 | −28 | −27 | −26 |
| Net financials | 7 | −10 | 29 | 25 | 1 150 |
| Profit before tax | −17 | 437 | 369 | 622 | 892 |
| Tax | −0 | −90 | −82 | −139 | −0 |
| Net profit | −17 | 347 | 287 | 483 | 892 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 851 | 2 627 | 2 446 | 2 154 | 2 993 |
| Equity | 1 374 | 1 536 | 1 636 | 1 924 | 2 612 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 | 100 | 185 | 230 | 381 |
| Total debt | 10 | 100 | 185 | 230 | 381 |
EBITDA margin
-2600000.0%
This company
15.8%
Market median
-16455796% vs market
20202024
Equity ratio
87.3%
This company
38.2%
Market median
+129% vs market
20202024
Return on equity
34.2%
This company
18.4%
Market median
+86% vs market
20202024
Net profit margin
89200000.0%
This company
8.1%
Market median
+1101234468% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
VU Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ukales Hälsokonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Valiant Untodione Ukale | Chief Executive Officer | 0 companies |
| Rolf Andreas Sjödin | Deputy Board Member | 0 companies |
| Lars Olof Hellman | Board of Directors | 0 companies |
| Anna Ingrid Iréne Lundberg | Deputy Board Member | 0 companies |